Novel drugs for oral anticoagulation pharmacotherapy

References

• Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133, 160S–198S (2008).
   PubMed Web of Science ®Google Scholar
• Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke Prevention With the Oral Direct Thrombin Inhibitor Ximelagatran Compared With Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): randomised controlled trial. Lancet362, 1691–1698 (2003).
   PubMed Web of Science ®Google Scholar
• Albers GW, Diener HC, Frison L et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA293, 690–698 (2005).
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann. Intern. Med.131, 927–934 (1999).
   PubMed Web of Science ®Google Scholar
• Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin. Pharmacokinet.47, 285–295 (2008).
   PubMed Web of Science ®Google Scholar
• Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation124, 1573–1579 (2011).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial. Lancet370, 949–956 (2007).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Huo MH et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, noninferiority trial. Thromb. Haemost.105, 721–729 (2011).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N et al. Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost.5, 2178–2185 (2007).
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Davidson BL, Comp PC et al. Oral thrombin inhibitor dabigatran etexilate versus North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty24, 1–9 (2009).
   PubMed Web of Science ®Google Scholar
• Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb. Haemost.101, 77–85 (2009).
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med.361, 2342–2352 (2009).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med.361, 1139–1151 (2009).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N. Engl. J. Med.363, 1875–1876 (2010).
   PubMed Web of Science ®Google Scholar
• Wann LS, Curtis AB, Ellenbogen KA et al. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). J. Am. Coll. Cardiol.57, 1330–1337 (2001).
   Google Scholar
• Beasley BN, Unger EF, Temple R. Anticoagulant options – why the FDA approved a higher but not a lower dose of dabigatran. N. Engl. J. Med.364, 1788–1790 (2011).
   PubMed Web of Science ®Google Scholar
• Oldgren J, Budaj A, Granger CB et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, Phase II trial. Eur. Heart J.32, 2781–2789 (2011).
   PubMed Web of Science ®Google Scholar
• Johansson S, Cullberg M, Eriksson UG et al. Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects. Int. J. Clin. Pharmacol. Ther.49, 258–267 (2011).
   PubMed Web of Science ®Google Scholar
• Lip GYH, Rasmussen LH, Olsson SB et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs vitamin K antagonists. Eur. Heart J.30, 2897–2907 (2009).
   PubMed Web of Science ®Google Scholar
• Perzborn E, Strassburger J, Wilmen A et al.In vitro and in vivo studies of the novel anti-thrombotic agent BAY 59–7939 – an oral, direct Factor Xa inhibitor. J. Thromb. Haemost.3, 514–521 (2005).
   PubMed Web of Science ®Google Scholar
• Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral Factor Xa inhibitor. Arterioscler. Thromb. Vasc. Biol.30, 376–381 (2010).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med.358, 2765–2775 (2008).
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet372, 31–39 (2008).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med.358, 2776–2786 (2008).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet373, 1673–1680 (2009).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Eriksson BI et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb. Haemost.105, 444–453 (2011).
   PubMed Web of Science ®Google Scholar
• Cohen AT, Spiro TE, Büller HR et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J. Thromb. Thrombolysis31, 407–416 (2011).
   PubMed Web of Science ®Google Scholar
• The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med.363, 2499–2510 (2010).
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med.365, 883–891 (2011).
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, Phase II trial. Lancet374, 29–38 (2009).
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD et al.; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med.366, 9–19 (2012).
   PubMed Web of Science ®Google Scholar
• Raghavan N, Frost CE, Yu Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab. Dispos.37, 74–81 (2009).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med.361, 594–604 (2009).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet375, 807–815 (2010).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N. Engl. J. Med.363, 2487–2498 (2010).
   PubMed Web of Science ®Google Scholar
• Huang J, Cao Y, Liao C, Wu L, Gao F. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb. Haemost.105, 245–253 (2011).
   PubMed Web of Science ®Google Scholar
• Leizorovicz A, Kakkar AK, Haas SK et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N. Engl. J. Med.365, 2167–2177 (2011).
   PubMedGoogle Scholar
• Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med.364, 806–817 (2011).
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med.365, 981–992 (2011).
   PubMed Web of Science ®Google Scholar
• Alexander JH, Becker RC, Bhatt DL et al. Apixaban, an oral, direct, selective Factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation119, 2877–2885 (2009).
   PubMed Web of Science ®Google Scholar
• Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl. J. Med.365, 699–708 (2011).
   PubMed Web of Science ®Google Scholar
• Ogata K, Mendell-Harary J, Tachibana M et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel Factor Xa inhibitor edoxaban in healthy volunteers. J. Clin. Pharmacol.50, 743–753 (2010).
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Antman EM et al. Evaluation of the novel Factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am. Heart J.160, 635–641 (2010).
   PubMed Web of Science ®Google Scholar
• Turpie AG. New oral anticoagulants in atrial fibrillation. Eur. Heart J.29, 155–165 (2008).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Turpie AG, Lassen MR et al. Prevention of venous thromboembolism with an oral Factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J. Thromb. Haemost.8, 714–721 (2010).
   PubMed Web of Science ®Google Scholar
• Steg G, Mehta SR, Jukema JM. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral Factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur. Heart J.32, 2541–2554 (2011).
   PubMed Web of Science ®Google Scholar
• Agnelli G, Haas S, Ginsberg JS, Krueger KA, Dmitrienko A, Brandt JT. A Phase II study of the oral Factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J. Thromb. Haemost.5, 746–753 (2007).
   PubMed Web of Science ®Google Scholar
• Weitz JI, Cao C, Eriksson BI et al. A dose-finding study with TAK-442, an oral Factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb. Haemost.104, 1150–1157 (2010).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Yusuf S, Ezekowitz MD et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet376, 975–983 (2010).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct Factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J. Thromb. Haemost.5, 2368–2375 (2007).
   PubMed Web of Science ®Google Scholar